A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as Add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Pharmacokinetics and Safety of CDP870 as Add-on Medication to MTX in Japanese Active RA Patients Who Have an Incomplete Response to MTX

Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 May 2016

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms J-RAPID
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Apr 2015 According to an Astellas Pharma media release, 4-year data from this study were presented at the Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology 2015.
    • 30 Oct 2013 Post-hoc analysis for clinical response with loading dose presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top